Sientra Inc (SIEN) Downgraded to “Sell” at Zacks Investment Research
Sientra Inc (NASDAQ:SIEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, Lake Street Capital started coverage on shares of Sientra in a report on Monday, April 17th. They set a “buy” rating and a $11.00 target price on the stock.
Sientra (NASDAQ:SIEN) traded down 1.67% on Wednesday, reaching $7.66. 71,069 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $8.17 and its 200 day moving average price is $8.44. Sientra has a 1-year low of $5.60 and a 1-year high of $10.37. The firm’s market capitalization is $144.26 million.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, May 9th. The medical instruments supplier reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by $0.12. The business had revenue of $7.50 million for the quarter, compared to analyst estimates of $5.98 million. Sientra had a negative return on equity of 44.19% and a negative net margin of 382.33%. Sientra’s revenue for the quarter was up 400.0% compared to the same quarter last year. On average, analysts expect that Sientra will post ($2.29) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Sientra Inc (SIEN) Downgraded to “Sell” at Zacks Investment Research” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/05/18/sientra-inc-sien-downgraded-to-sell-at-zacks-investment-research.html.
Several hedge funds have recently modified their holdings of the company. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Sientra by 321.9% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 545,694 shares of the medical instruments supplier’s stock worth $4,906,000 after buying an additional 416,340 shares during the period. Park West Asset Management LLC boosted its stake in shares of Sientra by 1.3% in the third quarter. Park West Asset Management LLC now owns 1,680,752 shares of the medical instruments supplier’s stock worth $15,110,000 after buying an additional 22,115 shares during the period. FNY Partners Fund LP acquired a new stake in shares of Sientra during the fourth quarter worth $180,000. WFG Advisors LP boosted its stake in shares of Sientra by 1,660.7% in the fourth quarter. WFG Advisors LP now owns 10,740 shares of the medical instruments supplier’s stock worth $600,000 after buying an additional 10,130 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Sientra by 0.3% in the first quarter. Wells Fargo & Company MN now owns 12,871 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 40 shares during the period. 69.34% of the stock is currently owned by institutional investors.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc and related companies with MarketBeat.com's FREE daily email newsletter.